Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer

Nucleic Acids Research

Volumn 40, Issue 14, 2012, Pages 6725-6740

  Stolzenburg, Sabine ^a,b   Rots, Marianne G ^a   Beltran, Adriana S ^b   Rivenbark, Ashley G ^b,c   Yuan, Xinni ^b   Qian, Haili ^d   Strahl, Brian D ^c,e   Blancafort, Pilar ^b,e  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Department of Pharmacology ^*  (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d CANCER HOSPITAL   (China)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR; KRUPPEL LIKE FACTOR; RETROVIRUS VECTOR; TRANSCRIPTION FACTOR SOX2; ZINC FINGER PROTEIN;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENHANCER REGION; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN FUNCTION; PROTEIN METHYLATION; PROTEIN MICROARRAY; PROTEIN TARGETING; TUMOR CELL; TUMOR XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA; FEMALE; GENE SILENCING; HUMANS; MICE; PROTEIN ENGINEERING; SOXB1 TRANSCRIPTION FACTORS; TRANSCRIPTION FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84864922025     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gks360     Document Type: Article

References (69)

1. Darnell, J.E. Jr (2002) Transcription factors as targets for cancer therapy. Nat. Rev. Cancer, 2, 740-749. (Pubitemid 37328909)
2. Ben-Porath, I., Thomson, M.W., Carey, V.J., Ge, R., Bell, G.W., Regev, A. and Weinberg, R.A. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet., 40, 499-507. (Pubitemid 351601215)
3. Perou, C.M. (2010) Molecular stratification of triple-negative breast cancers. Oncologist, 15(Suppl. 5), 39-48.
4. Perou, C.M., Sorlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., Pollack, J.R., Ross, D.T., Johnsen, H., Akslen, L.A. et al. (2000) Molecular portraits of human breast tumours. Nature, 406, 747-752.
5. Prat, A., Parker, J.S., Karginova, O., Fan, C., Livasy, C., Herschkowitz, J.I., He, X. and Perou, C.M. (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res., BCR, 12, R68.
6. Dontu, G. (2008) Breast cancer stem cell markers-the rocky road to clinical applications. Breast Cancer Res., 10, 110.
7. Honeth, G., Bendahl, P.O., Ringner, M., Saal, L.H., Gruvberger-Saal, S.K., Lovgren, K., Grabau, D., Ferno, M., Borg, A. and Hegardt, C. (2008) The CD44+/CD24-phenotype is enriched in basal-like breast tumors. Breast Cancer Res., 10, R53.
8. Park, S.Y., Lee, H.E., Li, H., Shipitsin, M., Gelman, R. and Polyak, K. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin. Cancer Res., 16, 876-887.
9. Tysnes, B.B. and Bjerkvig, R. (2007) Cancer initiation and progression: involvement of stem cells and the microenvironment. Biochim. Biophys. Acta, 1775, 283-297. (Pubitemid 46901154)
10. Marchini, C., Montani, M., Konstantinidou, G., Orru, R., Mannucci, S., Ramadori, G., Gabrielli, F., Baruzzi, A., Berton, G., Merigo, F. et al. Mesenchymal/stromal gene expression signature relates to basal-like breast cancers, identifies bone metastasis and predicts resistance to therapies. PLoS One, 5, e14131.
11. Fillmore, C.M. and Kuperwasser, C. (2008) Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res., 10, R25.
12. Wegner, M. (1999) From head to toes: the multiple facets of Sox proteins. Nucleic Acids Res., 27, 1409-1420. (Pubitemid 29206280)
13. Rao, R.R., Calhoun, J.D., Qin, X., Rekaya, R., Clark, J.K. and Stice, S.L. (2004) Comparative transcriptional profiling of two human embryonic stem cell lines. Biotechnol. Bioeng., 88, 273-286. (Pubitemid 39524247)
14. Wang, J., Rao, S., Chu, J., Shen, X., Levasseur, D.N., Theunissen, T.W. and Orkin, S.H. (2006) A protein interaction network for pluripotency of embryonic stem cells. Nature, 444, 364-368. (Pubitemid 44764111)
15. Adachi, K., Suemori, H., Yasuda, S.Y., Nakatsuji, N. and Kawase, E. (2010) Role of SOX2 in maintaining pluripotency of human embryonic stem cells. Genes Cells, 15, 455-470.
16. Boyer, L.A., Lee, T.I., Cole, M.F., Johnstone, S.E., Levine, S.S., Zucker, J.P., Guenther, M.G., Kumar, R.M., Murray, H.L., Jenner, R.G. et al. (2005) Core transcriptional regulatory circuitry in human embryonic stem cells. Cell, 122, 947-956. (Pubitemid 41345211)
17. Hochedlinger, K. and Plath, K. (2009) Epigenetic reprogramming and induced pluripotency. Development, 136, 509-523.
18. Sikorska, M., Sandhu, J.K., Deb-Rinker, P., Jezierski, A., Leblanc, J., Charlebois, C., Ribecco-Lutkiewicz, M., Bani-Yaghoub, M. and Walker, P.R. (2008) Epigenetic modifications of SOX2 enhancers, SRR1 and SRR2, correlate with in vitro neural differentiation. J. Neurosci. Res., 86, 1680-1693. (Pubitemid 351859420)
19. Beltran, A.S., Rivenbark, A.G., Richardson, B.T., Yuan, X., Quian, H., Hunt, J.P., Zimmerman, E., Graves, L.M. and Blancafort, P. (2011) Generation of tumor initiating cells by exogenous delivery of OCT4 Transcription Factor. Breast Cancer Research: BCR, 13, R94.
20. Otsubo, T., Akiyama, Y., Yanagihara, K. and Yuasa, Y. (2008) SOX2 is frequently downregulated in gastric cancers and inhibits cell growth through cell-cycle arrest and apoptosis. Br. J. Cancer, 98, 824-831. (Pubitemid 351272602)
21. Li, X.L., Eishi, Y., Bai, Y.Q., Sakai, H., Akiyama, Y., Tani, M., Takizawa, T., Koike, M. and Yuasa, Y. (2004) Expression of the SRY-related HMG box protein SOX2 in human gastric carcinoma. Int. J. Oncol., 24, 257-263.
22. Wilbertz, T., Wagner, P., Petersen, K., Stiedl, A.C., Scheble, V.J., Maier, S., Reischl, M., Mikut, R., Altorki, N.K., Moch, H. et al. (2011) SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Mod. Pathol., 24, 944-953.
23. Gangemi, R.M., Griffero, F., Marubbi, D., Perera, M., Capra, M.C., Malatesta, P., Ravetti, G.L., Zona, G.L., Daga, A. and Corte, G. (2009) SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells, 27, 40-48.
24. Lu, Y., Futtner, C., Rock, J.R., Xu, X., Whitworth, W., Hogan, B.L. and Onaitis, M.W. (2010) Evidence that SOX2 overexpression is oncogenic in the lung. PLoS One, 5, e11022.
25. Leung, E.L., Fiscus, R.R., Tung, J.W., Tin, V.P., Cheng, L.C., Sihoe, A.D., Fink, L.M., Ma, Y. and Wong, M.P. (2010) Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One, 5, e14062.
26. Bae, K.M., Su, Z., Frye, C., McClellan, S., Allan, R.W., Andrejewski, J.T., Kelley, V., Jorgensen, M., Steindler, D.A., Vieweg, J. et al. (2010) Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. J. Urol., 183, 2045-2053.
27. Xu, X.L., Xing, B.C., Han, H.B., Zhao, W., Hu, M.H., Xu, Z.L., Li, J.Y., Xie, Y., Gu, J., Wang, Y. et al. (2010) The properties of tumor-initiating cells from a hepatocellular carcinoma patient's primary and recurrent tumor. Carcinogenesis, 31, 167-174.
28. Lengerke, C., Fehm, T., Kurth, R., Neubauer, H., Scheble, V., Muller, F., Schneider, F., Petersen, K., Wallwiener, D., Kanz, L. et al. (2011) Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma. BMC Cancer, 11, 42.
29. Rodriguez-Pinilla, S.M., Sarrio, D., Moreno-Bueno, G., Rodriguez-Gil, Y., Martinez, M.A., Hernandez, L., Hardisson, D., Reis-Filho, J.S. and Palacios, J. (2007) Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod. Pathol., 20, 474-481. (Pubitemid 46482371)
30. Chen, Y., Shi, L., Zhang, L., Li, R., Liang, J., Yu, W., Sun, L., Yang, X., Wang, Y., Zhang, Y. et al. (2008) The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J. Biol. Chem., 283, 17969-17978.
31. Sera, T. (2009) Zinc-finger-based artificial transcription factors and their applications. Adv. Drug Deliv. Rev., 61, 513-526.
32. Tan, S., Guschin, D., Davalos, A., Lee, Y.L., Snowden, A.W., Jouvenot, Y., Zhang, H.S., Howes, K., McNamara, A.R., Lai, A. et al. (2003) Zinc-finger protein-targeted gene regulation: genomewide single-gene specificity. Proc. Natl Acad. Sci. USA, 100, 11997-12002. (Pubitemid 37271504)
33. Bartsevich, V.V. and Juliano, R.L. (2000) Regulation of the MDR1 gene by transcriptional repressors selected using peptide combinatorial libraries. Mol. Pharmacol., 58, 1-10. (Pubitemid 30452522)
34. Beerli, R.R., Segal, D.J., Dreier, B. and Barbas, C.F. 3rd (1998) Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks. Proc. Natl Acad. Sci. USA, 95, 14628-14633. (Pubitemid 29003681)
35. Laganiere, J., Kells, A.P., Lai, J.T., Guschin, D., Paschon, D.E., Meng, X., Fong, L.K., Yu, Q., Rebar, E.J., Gregory, P.D. et al. (2010) An engineered zinc finger protein activator of the endogenous glial cell line-derived neurotrophic factor gene provides functional neuroprotection in a rat model of Parkinson's disease. J. Neurosci., 30, 16469-16474.
36. Segal, D.J., Goncalves, J., Eberhardy, S., Swan, C.H., Torbett, B.E., Li, X. and Barbas, C.F. 3rd (2004) Attenuation of HIV-1 replication in primary human cells with a designed zinc finger transcription factor. J. Biol. Chem., 279, 14509-14519. (Pubitemid 38618838)
37. Beltran, A.S., Russo, A., Lara, H., Fan, C., Lizardi, P.M. and Blancafort, P. (2011) Suppression of breast tumor growth and metastasis by an engineered transcription factor. PLoS One, 6, e24595.
38. Beltran, A.S. and Blancafort, P. (2011) Reactivation of MASPIN in non-small cell lung carcinoma (NSCLC) cells by artificial transcription factors (ATFs). Epigenetics, 6, 224-235.
39. Gommans, W.M., McLaughlin, P.M., Lindhout, B.I., Segal, D.J., Wiegman, D.J., Haisma, H.J., van der Zaal, B.J. and Rots, M.G. (2007) Engineering zinc finger protein transcription factors to downregulate the epithelial glycoprotein-2 promoter as a novel anti-cancer treatment. Mol. Carcinog., 46, 391-401. (Pubitemid 46744459)
40. Sohn, J.H., Yeh, B.I., Choi, J.W., Yoon, J., Namkung, J., Park, K.K. and Kim, H.W. (2010) Repression of human telomerase reverse transcriptase using artificial zinc finger transcription factors. Mol. Cancer Res., 8, 246-253.
41. Lund, C.V., Popkov, M., Magnenat, L. and Barbas, C.F. 3rd (2005) Zinc finger transcription factors designed for bispecific coregulation of ErbB2 and ErbB3 receptors: insights into ErbB receptor biology. Mol. Cell. Biol., 25, 9082-9091. (Pubitemid 41429096)
42. Mandell, J.G. and Barbas, C.F. 3rd (2006) Zinc finger tools: custom DNA-binding domains for transcription factors and nucleases. Nucl. Acids Res., 34, W516-523. (Pubitemid 44529824)
43. Beltran, A., Parikh, S., Liu, Y., Cuevas, B.D., Johnson, G.L., Futscher, B.W. and Blancafort, P. (2007) Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors. Oncogene, 26, 2791-2798. (Pubitemid 46663828)
44. Liu, Q., Segal, D.J., Ghiara, J.B. and Barbas, C.F. 3rd (1997) Design of polydactyl zinc-finger proteins for unique addressing within complex genomes. Proc. Natl Acad. Sci. USA, 94, 5525-5530. (Pubitemid 27241802)
45. Rae, J.M., Creighton, C.J., Meck, J.M., Haddad, B.R. and Johnson, M.D. (2007) MDA-MB-435 cells are derived from M14 melanoma cells-a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res. Treatment, 104, 13-19. (Pubitemid 46976633)
46. Chambers, A.F. (2009) MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res., 69, 5292-5293.
47. Hennessy, B.T., Gonzalez-Angulo, A.M., Stemke-Hale, K., Gilcrease, M.Z., Krishnamurthy, S., Lee, J.S., Fridlyand, J., Sahin, A., Agarwal, R., Joy, C. et al. (2009) Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res., 69, 4116-4124.
48. Blancafort, P., Magnenat, L. and Barbas, C.F. 3rd (2003) Scanning the human genome with combinatorial transcription factor libraries. Nat. Biotechnol., 21, 269-274. (Pubitemid 36314810)
49. Magnenat, L., Blancafort, P. and Barbas, C.F. 3rd (2004) In vivo selection of combinatorial libraries and designed affinity maturation of polydactyl zinc finger transcription factors for ICAM-1 provides new insights into gene regulation. J. Mol. Biol., 341, 635-649. (Pubitemid 39118402)
50. Beltran, A., Liu, Y., Parikh, S., Temple, B. and Blancafort, P. (2006) Interrogating genomes with combinatorial artificial transcription factor libraries: asking zinc finger questions. Assay Drug Dev. Technol., 4, 317-331. (Pubitemid 44083586)
51. Blancafort, P., Tschan, M.P., Bergquist, S., Guthy, D., Brachat, A., Sheeter, D.A., Torbett, B.E., Erdmann, D. and Barbas, C.F. 3rd (2008) Modulation of drug resistance by artificial transcription factors. Mol. Cancer Ther., 7, 688-697. (Pubitemid 351482151)
52. Blancafort, P., Chen, E.I., Gonzalez, B., Bergquist, S., Zijlstra, A., Guthy, D., Brachat, A., Brakenhoff, R.H., Quigley, J.P., Erdmann, D. et al. (2005) Genetic reprogramming of tumor cells by zinc finger transcription factors. Proc. Natl Acad. Sci. USA, 102, 11716-11721. (Pubitemid 41170792)
53. Groner, A.C., Meylan, S., Ciuffi, A., Zangger, N., Ambrosini, G., Denervaud, N., Bucher, P. and Trono, D. (2010) KRAB-zinc finger proteins and KAP1 can mediate long-range transcriptional repression through heterochromatin spreading. PLoS Genet, 6, e1000869.
54. Leis, O., Eguiara, A., Lopez-Arribillaga, E., Alberdi, M.J., Hernandez-Garcia, S., Elorriaga, K., Pandiella, A., Rezola, R. and Martin, A.G. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene, 31, 1354-1365.
55. Bass, A.J., Watanabe, H., Mermel, C.H., Yu, S., Perner, S., Verhaak, R.G., Kim, S.Y., Wardwell, L., Tamayo, P., Gat-Viks, I. et al. (2009) SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat. Genet., 41, 1238-1242.
56. Hussenet, T., Dali, S., Exinger, J., Monga, B., Jost, B., Dembele, D., Martinet, N., Thibault, C., Huelsken, J., Brambilla, E. et al. (2010) SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One, 5, e8960.
57. Challen, G.A., Sun, D., Jeong, M., Luo, M., Jelinek, J., Berg, J.S., Bock, C., Vasanthakumar, A., Gu, H., Xi, Y. et al. (2011) Dnmt3a is essential for hematopoietic stem cell differentiation. Nat. Genet., 44, 23-31.
58. Epsztejn-Litman, S., Feldman, N., Abu-Remaileh, M., Shufaro, Y., Gerson, A., Ueda, J., Deplus, R., Fuks, F., Shinkai, Y., Cedar, H. et al. (2008) De novo DNA methylation promoted by G9a prevents reprogramming of embryonically silenced genes. Nat. Struct. Mol. Biol., 15, 1176-1183.
59. Christophersen, N.S. and Helin, K. (2010) Epigenetic control of embryonic stem cell fate. J. Exp. Med., 207, 2287-2295.
60. Schoenhals, M., Kassambara, A., De Vos, J., Hose, D., Moreaux, J. and Klein, B. (2009) Embryonic stem cell markers expression in cancers. Biochem. Biophys. Res. Commun., 383, 157-162.
61. Oppel, F., Muller, N., Schackert, G., Hendruschk, S., Martin, D., Geiger, K.D. and Temme, A. (2011) SOX2-RNAi attenuates S-phase entry and induces RhoA-dependent switch to protease-independent amoeboid migration in human glioma cells. Mol. Cancer, 10, 137.
62. Rivenbark, A.G., Stolzenburg, S., Beltran, A.S., Yuan, X., Rots, M.G., Strahl, B.D. and Blancafort, P. (2012) Epigenetic reprogramming of cancer cells via targeted DNA methylation. Epigenetics, 7, 350-360.
63. Margolin, J.F., Friedman, J.R., Meyer, W.K., Vissing, H., Thiesen, H.J. and Rauscher, F.J. 3rd (1994) Kruppel-associated boxes are potent transcriptional repression domains. Proc. Natl Acad. Sci. USA, 91, 4509-4513.
64. Alonso, M.M., Diez-Valle, R., Manterola, L., Rubio, A., Liu, D., Cortes-Santiago, N., Urquiza, L., Jauregi, P., de Munain, A.L., Sampron, N. et al. (2011) Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. PLoS One, 6, e26740.
65. Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 455, 1061-1068.
66. Mikkelsen, T.S., Ku, M., Jaffe, D.B., Issac, B., Lieberman, E., Giannoukos, G., Alvarez, P., Brockman, W., Kim, T.K., Koche, R.P. et al. (2007) Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature, 448, 553-560. (Pubitemid 47206934)
67. Chen, Y., Bathula, S.R., Li, J. and Huang, L. (2010) Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J. Biol. Chem., 285, 22639-22650.
68. van der Gun, B.T., Wasserkort, R., Monami, A., Jeltsch, A., Rasko, T., Slaska-Kiss, K., Cortese, R., Rots, M.G., de Leij, L.F., Ruiters, M.H. et al. (2008) Persistent downregulation of the pancarcinoma-associated epithelial cell adhesion molecule via active intranuclear methylation. Int. J. Cancer, 123, 484-489. (Pubitemid 351842037)
69. Beltran, A.S., Sun, X., Lizardi, P.M. and Blancafort, P. (2008) Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor. Mol. Cancer Ther., 7, 1080-1090.